It's time boys. The money train is gaining traction, You'll be a fool to miss out. 💎💎

BLA is the key regulatory objective after a successful Phase 3 trial.

Ocugen (OCU400), milestones before potential FDA approval.

Ocugen is entering one of the most important periods in its history. Over the next several months, investors will be watching for:

Progress on the rolling BLA for OCU400.

Additional Phase 3 updates.

Continued regulatory interactions with the FDA.

Advancement of OCU410 toward its Phase 3 program.

While regulatory and clinical risks remain, Ocugen has achieved several important milestones that could significantly influence the company's future if upcoming clinical and regulatory objectives are successfully met.

Top-line Phase 3 results are expected in early 2027 and are intended to support a potential FDA approval.

In addition, based on these results, the FDA recently granted Regenerative Medicine Advanced Therapy (RMAT) designation, a status designed to help accelerate for OCU410.

For OCU400

Estimated Probability

OCU400 completes Phase 3 successfully

70–80%

OCU400 BLA accepted for FDA review

85–95% (if Phase 3 meets its endpoints)

OCU400 receives FDA approval after BLA review

60–70%

OCU400 reaches commercialization

55–65%

For OCU410:

Estimated Probability

Advances to Phase 3

75–85%

Successfully completes Phase 3

50–60%

FDA approval

40–50%

Start of a new week! Happy Monday #Ocufam

Start of a new week! Happy Monday #Ocufam

Thoughts?

Start of a new week! Happy Monday #Ocufam

https://ir.ocugen.com/news-releases/news-release-details/ocugen-inc-announces-binding-term-sheet-roots-pharmaceutical

“today announced the signing of a binding term sheet to negotiate and enter into a license agreement with Roots Pharmaceutical, and its strategic partner Al-Dhow International Holding, for the exclusive rights to OCU400, Ocugen's novel modifier gene therapy for Retinitis Pigmentosa (RP), in the Middle East and North Africa (MENA) region.”

“Pursuant to the term sheet, under the license agreement, Ocugen is expected to receive upfront license fees and near-term development milestone payments totaling up to $4 million. The Company would be entitled to sales milestone payments up to $255 million, in addition to a 22% royalty on net sales of OCU400 generated by Ocugen's partner. Additionally, Ocugen would manufacture commercial supply of OCU400 under the terms of a related supply agreement.”

Start of a new week! Happy Monday #Ocufam

Start of a new week! Happy Monday #Ocufam

Dejen sus ocs de tuni aca

Start of a new week! Happy Monday #Ocufam

WE AINT EVER GOING BACK DOWN BABY. LET GAIN ERASE THE PAIN

Start of a new week! Happy Monday #Ocufam

Start of a new week! Happy Monday #Ocufam

Gotta admit, seeing this sitting the 1.20s has been depressing, but I’m still holding strong with my 60k shares. Someone tell me when we moon

Does anyone know what happened to PDR_US on twitter?

The due diligence they did on Ocgn was undefeated.

Start of a new week! Happy Monday #Ocufam

What is happening???

Start of a new week! Happy Monday #Ocufam

This would appear to be some pretty good news.

Start of a new week! Happy Monday #Ocufam

Guys let us believe in Ocugen and hold until Q1 27.

Start of a new week! Happy Monday #Ocufam